文献速递肿瘤 PET/CT放射性药物与辐射防护

β3肾上腺素能受体激动剂对老年患者正电子发射断层显像图像中棕色脂肪组织[18F]氟脱氧葡萄糖摄取的影响

Effect of β3-adrenergic receptor agonists on [18F] fluorodeoxyglucose uptake in brown adipose tissues in positron emission tomography images of elderly patients.
PubMed 文献 · EJNMMI Res · 2025-08-04

本研究回顾性分析44例≥60岁患者的[18F]FDG PET图像,按是否使用β3肾上腺素能受体激动剂分组,在8个预设感兴趣区进行视觉分析和SUVmax测量。结果显示肾周区摄取在用药组较未用药组显著增高(视觉分析p<0.001,SUVmax p=0.030),所有用药患者椎旁区均见摄取增高。作者认为β3肾上腺素能受体激动剂治疗似与老年患者[18F]FDG棕色脂肪摄取增高相关,尤其肾周区。

要点

  • 44例≥60岁患者中,肾周区[18F]FDG棕色脂肪摄取在β3激动剂组较未用药组显著增高。
  • 所有使用β3激动剂的患者椎旁区均出现[18F]FDG棕色脂肪摄取增高。
  • 作者认为β3激动剂治疗似与老年患者棕色脂肪摄取增高相关。

核心结论

  • 在≥60岁患者中,β3肾上腺素能受体激动剂治疗似与[18F]FDG棕色脂肪摄取增高相关,尤其肾周区。

研究设计与样本

  • 回顾性研究,纳入44例≥60岁患者,每例接受一次[18F]FDG PET扫描。
  • 分析8个预设感兴趣区:颈部、锁骨上、腋窝、纵隔、椎旁、腹主动脉旁、肾周和脾周区,进行视觉分析和SUVmax测量。
  • 查阅患者用药史和临床记录,评估β3肾上腺素能受体激动剂使用与[18F]FDG PET检查的关系。

主要发现

  • 肾周区[18F]FDG棕色脂肪摄取在β3激动剂组较未用药组显著增高:视觉分析p<0.001,SUVmax测量p=0.030。
  • 所有使用β3肾上腺素能受体激动剂的患者椎旁区均显示[18F]FDG棕色脂肪摄取增高。

关键数值与推荐

  • 肾周区视觉分析:β3激动剂组较未用药组显著增高(p<0.001)。
  • 肾周区SUVmax:β3激动剂组较未用药组显著增高(p=0.030)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Brown adipose tissues (BAT) are highly vascularized, mitochondria-rich tissues involved in thermogenesis. Physiological [18F]fluorodeoxyglucose ([18F]FDG) uptake in BAT can be influenced by several factors, including the use of medications that act on β-adrenergic receptors. Recently, increased [18F]FDG BAT uptake has been observed in elderly patients (≥ 60 years old) receiving β3-adrenergic receptor agonists. With the increasing use of β3-adrenergic receptor agonists for managing overactive bladder, there is limited understanding of their potential association with increased [18F]FDG BAT uptake. This study retrospectively investigated whether treatment with β3-adrenergic receptor agonists is associated with increased [18F]FDG BAT uptake among elderly patients. [18F]FDG positron emission tomography (PET) images were analyzed visually and through SUVmax measurements across eight predefined regions of interest (ROI): cervical, periclavicular, axillary, mediastinal, paravertebral, paraabdominal aortic, perirenal, and perisplenic regions. Patients' medication history and clinical records were reviewed to assess β3-adrenergic receptor agonist use relative to their [18F]FDG PET study. RESULTS: Forty-four elderly patients, each with a single [18F]FDG PET scan, were included in the analysis. Among the eight ROIs, the perirenal region showed a statistically significant increase in [18F]FDG BAT uptake in patients receiving β3-adrenergic receptor agonists compared with those not receiving, based on both visual analysis (p < 0.001) and SUVmax measurements (p = 0.030). All patients receiving β3-adrenergic receptor agonists demonstrated increased [18F]FDG BAT uptake in the paravertebral region. CONCLUSION: In patients aged ≥ 60 years, β3-adrenergic receptor agonist therapy appears to be associated with increased [18F]FDG BAT uptake, particularly in the perirenal area.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Gacula JKV, Ogane K, Fuse K, et al. Effect of β3-adrenergic receptor agonists on [18F] fluorodeoxyglucose uptake in brown adipose tissues in positron emission tomography images of elderly patients. EJNMMI Res. 2025. PMID: 40760284. doi:10.1186/s13550-025-01286-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。